Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Cardiac stress test, Chest pain, Nausea, Pyrexia
Clinical narrative: Patient had chest pain after her second Moderna Covid-19 vaccine; patient was so weak she could not sit up; mild temperature; nauseous; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (Patient had chest pain after her second Moderna Covid-19 vaccine) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026A21A and 030L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Coronary artery disease.   On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Mar-2021, the patient experienced ASTHENIA (patient was so weak she could not sit up), PYREXIA (mild temperature) and NAUSEA (nauseous). On 11-Mar-2021, the patient experienced CHEST PAIN (Patient had chest pain after her second Moderna Covid-19 vaccine) (seriousness criterion medically significant). At the time of the report, CHEST PAIN (Patient had chest pain after her second Moderna Covid-19 vaccine), ASTHENIA (patient was so weak she could not sit up), PYREXIA (mild temperature) and NAUSEA (nauseous) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Cardiac stress test: normal (normal) normal. In 2021, Ultrasound scan: normal (normal) normal.         Patient did not have history of COVID-19. No history of Myocarditis or pericarditis was reported. No concomitant medication was reported. Two days after her second Moderna Covid-19 vaccine, the patient was admitted to the hospital for a cardiac evaluation. The patient was not diagnosed with Myocarditis or pericarditis. On 04 -Dec-2021, the patient received first booster Moderna Covid-19 vaccine (lot number 030801B). Patient was having trouble reading the lot number on her vaccination card) expiration date was not provided. The patient did not report any adverse reactions or side effects after her booster dose. Patient was discharged. Not conclusive if patient's symptoms were related to the Moderna Covid-19 vaccine. No treatment information was reported. Company Comment: This is a Spontaneous case concerning an 82-year-old female patient, with reported concurrent condition of coronary artery disease, who experienced the serious unexpected adverse event of Chest pain (medically Significant) and Cardiac Monitoring that leads to hospitalization. Also, other non-serious adverse events were reported in this case as Asthenia, Pyrexia and Nausea. The event of chest pain occurred in an unknown date after the administration of the second dose of the mRNA-1273 vaccine and the Cardiac Monitoring was performed approximately two days after the administration of the second dose of the mRNA-1273 vaccine. Relevant tests were performed: stress test and an ultrasound with no abnormalities. The reported concurrent condition and patient age remains as a contributor for the event Chest pain. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. The case was assessed as serious.   Most recent FOLLOW-UP information incorporated above includes: On 14-Apr-2022: Follow-up received contains no new information (NNI).; Sender's Comments: This is a Spontaneous case concerning an 82-year-old female patient, with reported concurrent condition of coronary artery disease, who experienced the serious unexpected adverse event of Chest pain (medically Significant) and Cardiac Monitoring that leads to hospitalization. Also, other non-serious adverse events were reported in this case as Asthenia, Pyrexia and Nausea. The event of chest pain occurred in an unknown date after the administration of the second dose of the mRNA-1273 vaccine and the Cardiac Monitoring was performed approximately two days after the administration of the second dose of the mRNA-1273 vaccine. Relevant tests were performed: stress test and an ultrasound with no abnormalities. The reported concurrent condition and patient age remains as a contributor for the event Chest pain. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. The case was assessed as serious.